Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology
Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021 It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the…
